Abstract Wed092: Embracing the complex pathophysiology of heart failure with preserved ejection fraction by developing rodent models to feature different patients’ phenogroups
Abstract
Heart failure
with preserved ejection fraction (HFpEF) is complex clinical phenotype associated with multiple comorbidities; type2 diabetes, obesity, metabolic syndrome, Metabolic Dysfunction associated Steatohepatitis (MASH).
No animal model captures all HFpEF variables. Thus, it is important to develop different models each replicating some features to optimize bench-to-bed translation.
We developed
3 models each representing specific phenogroup of patients. Empagliflozin (EMPA), clinically proven SGLT-2i was used for validation.
Methods:
MASH related HFpEF was induced in male Golden Syrian hamsters fed free choice diet (free access to control chow/water or high fat/high cholesterol diet+10% fructose water). HFpEF associated with metabolic disorders was induced in C57Bl6N mice fed high-fat diet (60% kcal from fat) and water with L-NAME (0.5 g/L) for 5 weeks. Spontaneously Diabetic Torii (SDT) fatty rat was characterized as a model of diabetes/obesity-related HFpEF. EMPA or vehicle was administered orally at 10mg/kg for at least 3 weeks before evaluation of cardiac function by echocardiography and invasive hemodynamics.
Results:
While the systolic function was preserved in all models, different stages of diastolic dysfunction were observed. In HFD+L-NAME model, mild diastolic dysfunction characterized by pseudo-normal profiles was observed (E/A=1.2±0.04 E/E’= 16.2±0.9 in HFD/L-NAME vs E/A=1.4 ± 0.02 E/E’= 14.4±0.4 in control). Restrictive pattern (i.e. grade 3 diastolic…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.